6-乙氧基-1,2,3,4-四氢萘 | 622834-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 中文名称: 6-乙氧基-1,2,3,4-四氢萘
• 英文名称: ethyl-(5,6,7,8-tetrahydro-[2]naphthyl)-ether
• 英文别名: Aethyl-(5,6,7,8-tetrahydro-[2]naphthyl)-aether；6-Aethoxy-1.2.3.4-tetrahydro-naphthalin；Aethyl-tetralyl-(6)-aether；6-Aethoxy-tetralin；ethyl 5,6,7,8-tetrahydronaphthalen-2-yl ether；6-Ethoxy-1,2,3,4-tetrahydronaphthalene
• CAS: 622834-96-2
• 化学式: C₁₂H₁₆O
• 分子量: 176.258
• InChiKey: RVMKZKUFOFFSCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-乙氧基-1,2,3,4-四氢萘 在 盐酸 、 三氯化铝 、 amalgamated zinc 、 phosphorus pentoxide 、 溶剂黄146 、 硝基苯 、 甲苯 作用下， 生成 10-ethoxy-2,3,5,6,7,8-hexahydro-1H-phenanthren-4-one
  参考文献：
  名称：

  Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis

  摘要：

  Background: This study evaluated the conjunctival effects of latanoprost and timolol. both of which contain benzalkonium. chloride, in patients with primary open-angle glaucoma (POAG), with and without a history of allergic conjunctivitis (AC). Methods: Two groups of 25 patients with and without a positive history for AC were studied. After a 21-day wash-out period patients were randomized to 14 days treatment with latanoprost or with timolol, in a cross-over fashion. The following parameters were evaluated on days 0 and 14: number of white blood cells, ferning test. conjunctival impression cytology, subjective symptoms, and objective ocular changes. Results: Latanoprost caused: (a) an increase in eosinophils in both groups and reduction in lymphocytes only in the group with a history of AC; (b) alterations in ferning test and impression cytology only in AC patients; and (c) development of subjective symptoms and objective signs only in non-AC glaucomatous subjects. Timolol therapy was responsible only for the occurrence of subjective symptoms and objective signs in non-AC patients. Conclusion: Latanoprost treatment induces ocular surface changes which are more evident in POAG patients who are also affected by AC. These findings are probably related to the very high latanoprost concentration of benzalkonium chloride and to its bedtime administration, which further amplifies the toxicity.

  DOI：

  10.1007/s004170100328
• 作为产物：
  描述：

  乙位萘乙醚 在 Fuller's Earth 、 镍 、 萘烷 作用下， 60.0 ℃ 、5.39 MPa 条件下， 生成 6-乙氧基-1,2,3,4-四氢萘
  参考文献：
  名称：

  US1918648

  摘要：

  公开号：

文献信息

• [EN] SUBSTITUTED PYRAZINE DERIVATIVES<br/>[FR] DERIVES PYRAZINIQUES SUBSTITUES
  申请人：UPJOHN CO

  公开号：WO2003091225A1

  公开（公告）日：2003-11-06

  The present invention provides substituted pyrazine derivatives of Formula (I), that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

  本发明提供了式（I）的取代吡嗪衍生物，其为CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及利用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是与焦虑有关的疾病和情绪障碍。
• [EN] SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF<br/>[FR] TRIAZOLOPYRIDINES SUBSTITUÉES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2014153037A1

  公开（公告）日：2014-09-25

  The invention provides compounds having the general formula: [insert formula (I)] (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

  该发明提供了具有一般式：[插入式(I)] (I)及其药学上可接受的盐的化合物，其中变量RA，下标n，环A，X2，L，下标m，X1，R1，R2，R3，R4和RN的含义如本文所述，并包含这种化合物的组合物和使用这种化合物和组合物的方法。
• Georg kalischer and heinz scheyer
  申请人：——

  公开号：US01807693A1

  公开（公告）日：1931-06-02

  311,208. Carpmael, A., (I. G. Farbenindustrie Akt.-Ges.). Feb. 6, 1928. Aldehydes; aldazines. - Aldehyde groups are introduced into cyclic compounds containing labile hydrogen atoms, in which other hydrogen atoms may be replaced by halogens or other monovalent substituents, except amino groups, by treatment with formamide or with derivatives thereof in which one of the hydrogen atoms of the amino group is substituted by aryl, and the other by alkyl, aralkyl on aryl, in the presence of an acid condensing agent containing chlorine, such as a chloride or oxychloride of phosphorus or sulphur or aluminium chloride. Suitable cyclic compounds are m-xylene, anthracene, N- ethylcarbazol, pyridine, quinoline, naphthostyril, naphtholethers, naphthalene, thioethers, oxythionaphthenes and anthrone and its nuclear substi. tution products. When using the formyl derivatives of secondary amines and cyclic compounds, such as oxythionaphthene and anthrone, containing in ring combination a methylene group and a Ketonic group capable of reacting in the tautomeric enolic form, chlorinated aldehydic derivatives are obtained, the hydroxyl group of the enolic form being replaced by chlorine. The reaction may be carried out in the presence of indifferent organic solvents. In examples, the following products are obtained, using formylmonomethylaniline and phosphorus oxychloride, in some cases in the presence of benzene : (1) panisaldehyde from anisol, (2) 2-ethoxy-1-naphthaldehyde from #-naphtholethylether, and 1-methoxy-5 : 6 : 7 : 8-tetrahydronaphthalene-4-aldehyde and 2-methoxy-5: 6 : 7 : 8-tetrahydronaphthalene. 1-aldehyde from 1- and 2-methoxy-5: 6 : 7 : 8. tetrahydronaphthalene, (3) anthracene-9-aldehyde from anthracene, and 1: 3-dimethyl-benzene-4- aldehyde from m-xylene, (4) a-chloranthracene-9- aldehyde from a-chloranthracene, and (5) 2- and 4-oxy-1-naphthaldehyde from #- and a-naphthol. In these examples, thionyl or sulphuryl chloride, or aluminium chloride may be used instead of phosphorus oxychloride, and other formylated secondary amines, such as formyldiphenylamine, or formamide, instead of formylmonomethylaniline. In a similar manner, 2: 7-dioxynaphthalene-1-aldehyde is obtained from 2: 7-dioxynaphthalene, 4: 8-dioxynaphthalene-1-aldehyde from 1: 5-dioxynaphthalene, 2-oxynaphthalene-1- aldehyde-3-carboxylic acid and the corresponding anilide from 2: 3-oxynaphthoic acid and its anilide, 2: 5-dimethyl-4-oxybenzaldehyde from pxylenol, 2: 4-dioxybenzaldehyde from resorcinol, and vanillin from guaiacol. In further examples, (6) 4-methyl-6-chlor-3-oxythionaphthene-2-aldehyde is obtained by heating 4-methyl-6-chlor-3- oxythionaphthene with formamide and anhydrous aluminium chloride or phosphorus oxychloride, (7) 6-ethoxy-3-oxythionaphthene-2-aldehyde is similarly obtained from 6-ethoxy-3-oxythionaphthene (8) N-ethylcarbazol is converted into an aldehyde by heating with formylmonomethylaniline and phosphorus oxychloride; pyridine and quinoline also yield aldehydes when similarly treated, and (9) naphthostyrilaldehyde is similarly obtained from naphthostyril. In further examples, in which chlorine is introduced at the same time as the aldehyde group, (10) 3-chlor-6-ethoxythionaphthene-2-aldehyde is obtained by treating 6. ethoxy-3-oxythionaphthene with formylmonomethylaniline and phosphorus oxychloride; 4- methyl-6-chlor-3-oxythionaphthene when similarly treated yields 4-methyl 3: 6 - dichlorthionaphthene-2-aldehyde, and (11) anthrone, when treated with formylmonomethylaniline or formyl. diphenylamine and phosphorus oxychloride yields 9-chloranthracene-10-aldehyde; when similarly treated, 2-chloranthrone yields 3: 10-dichloranthracene-9-aldehyde, 1 : 5-dichloranthrone yields 1: 5: 10-trichloranthracene-9-aldehyde, and desoxy-alizarine-dimethylether yields 1: 2-dimethnxy-lO-chloranthracene-9-nldehyde. The aldazines of most of the products are described.

  311,208. Carpmael, A., (I. G. Farbenindustrie Akt.-Ges.). Feb. 6, 1928. 醛类化合物；醛肼。- 醛基被引入含有活泼氢原子的环状化合物中，其中其他氢原子可以被卤素或其他一价取代基（除氨基外）所取代，通过与甲酰胺或其衍生物处理，其中氨基的一个氢原子被芳基取代，另一个被烷基、芳基烷基或芳基取代，存在含氯的酸性缩合剂的情况下进行，如磷或硫或铝氯化物的氯化物或氧氯化物。适合的环状化合物是间二甲苯，蒽，N-乙基咔唑，吡啶，喹啉，萘基苯，萘醚，萘，硫醚，氧硫萘烯和蒽醌及其核取代产物。当使用二级胺和环状化合物的甲酰衍生物，如氧硫萘烯和蒽醌，其中环中组合了一个甲基和一个酮基，能够以互变式烯醇形式反应时，得到氯代醛衍生物，烯醇形式的羟基被氯取代。该反应可在惰性有机溶剂存在下进行。在示例中，使用甲酰单甲基苯胺和磷氧氯化物，在某些情况下，在苯的存在下，得到以下产品：（1）苯甲醛，（2）2-乙氧基-1-萘甲醛，从 #-萘醚，和 1-甲氧基-5:6:7:8-四氢萘-4-甲醛和 2-甲氧基-5:6:7:8-四氢萘烯-1-甲醛从 1-和 2-甲氧基-5:6:7:8-四氢萘烯，（3）蒽-9-甲醛从蒽，和 1:3-二甲基苯-4-甲醛从间二甲苯，（4）α-氯蒽-9-甲醛从α-氯蒽，和（5）2-和 4-氧基-1-萘甲醛从 #-和 α-萘酚。在这些示例中，可以使用亚硫酰氯或硫酰氯，或铝氯化物代替磷氧氯化物，以及其他甲酰化的二级胺，如甲酰二苯胺，或甲酰胺，代替甲酰单甲基苯胺。以类似的方式，从 2:7-二氧基萘烯得到 2:7-二氧基萘烯-1-甲醛，从 1:5-二氧基萘烯得到 4:8-二氧基萘烯-1-甲醛，从 2:3-氧基萘甲酸和其酰胺得到 2-氧基萘烯-1-甲醛-3-羧酸和相应的苯胺，从对甲酚得到 2:5-二甲基-4-氧基苯甲醛，从邻苯二酚得到 2:4-二氧基苯甲醛，从愈创木酚得到香草醛。在进一步的示例中，（6）4-甲基-6-氯-3-氧基硫萘烯-2-甲醛通过加热 4-甲基-6-氯-3-氧基硫萘烯与甲酰胺和无水氯化铝或磷氧氯化物得到，（7）6-乙氧基-3-氧基硫萘烯-2-甲醛同样是通过 6-乙氧基-3-氧基硫萘烯得到（8）N-乙基咔唑通过与甲酰单甲基苯胺和磷氧氯化物加热转化为醛；吡啶和喹啉同样在类似处理时产生醛，（9）萘基苯甲醛同样是从萘基苯甲醛中得到。在进一步的示例中，同时引入氯和醛基时，（10）3-氯-6-乙氧硫萘烯-2-甲醛通过处理 6-乙氧基-3-氧基硫萘烯与甲酰单甲基苯胺和磷氧氯化物得到；4-甲基-6-氯-3-氧基硫萘烯在类似处理时产生 4-甲基-3:6-二氯硫萘烯-2-甲醛，以及（11）蒽醌，当与甲酰单甲基苯胺或甲酰二苯胺和磷氧氯化物处理时得到 9-氯蒽-10-甲醛；类似处理时，2-氯蒽醌得到 3:10-二氯蒽-9-甲醛，1:5-二氯蒽醌得到 1:5:10-三氯蒽-9-甲醛，去氧基紫嫣甲醛二甲醚得到 1:2-二甲氧-10-氯蒽-9-醛。大多数产品的醛肼已被描述。
• Substituted pyrazine derivatives
  申请人：——

  公开号：US20040053941A1

  公开（公告）日：2004-03-18

  The present invention provides substituted pyrazine derivatives of Formula I, 1 that are CRF 1 receptor antagonists, including human CRF 1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

  本发明提供了式I,1的取代吡嗪衍生物，它们是CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及使用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是焦虑相关疾病和情绪障碍。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。